CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.

Saved in:
Bibliographic Details
Title: CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer.
Authors: Xu H; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Gitto SB; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Ho GY; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia., Medvedev S; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Shield-Artin K; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia., Kim H; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Beard S; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia., Kinose Y; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Wang X; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Barker HE; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia., Ratnayake G; The Royal Women's Hospital, Parkville, VIC 3052, Australia., Hwang WT; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA., Hansen RJ; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW 2145, Australia., Strouse B; Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada., Milutinovic S; Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada., Hassig C; Sierra Oncology, Inc, 885 West Georgia Street, Suite 2150, Vancouver, BC V6C 3E8, Canada., Wakefield MJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia., Vandenberg CJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia., Scott CL; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.; Department of Medical Biology, University of Melbourne, Parkville, VIC 3010, Australia.; The Royal Women's Hospital, Parkville, VIC 3052, Australia.; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3010, Australia.; Sir Peter MacCallum Cancer Centre Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia., Simpkins F; Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Corporate Authors: Australian Ovarian Cancer Study
Source: IScience [iScience] 2024 May 15; Vol. 27 (7), pp. 109978. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2589-0042
DOI:10.1016/j.isci.2024.109978